Even before this week’s spate of IPOs, this year’s class of newly public biotechs on NASDAQ had surpassed that of 2017 in terms of funds raised, leaving this year’s class within striking distance of 2015’s...

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...

A compressed calendar, rather than investor overexuberance, accounts for one of the busiest weeks for IPO pricings in the sector’s history. Seven NASDAQ IPOs were completed during the week ending June 22, raising a total...

Four bankers who spoke with BioCentury said January’s biotech follow-on market has benefited from positive investor sentiment and an influx of generalists driven by a combination of tax reform and increased M&A. Biotechs raised $4...

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...

Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for now...

January’s class of follow-ons met investor and banker expectations by posting amuch smaller discount than last January’s crop, but a lack of catalysts to drive interest has made the buyside selective. Biotechs raised $943.2 million...